Related references
Note: Only part of the references are listed.Clinical Pharmacokinetics and Drug-Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension
Juergen Venitz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan
Shirin Bruderer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans
P.L.M. van Giersbergen et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan
Shirin Bruderer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)
R. Loch Macdonald et al.
LANCET NEUROLOGY (2011)
Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage
Alejandro A. Rabinstein et al.
LANCET NEUROLOGY (2010)
Preventing Vasospasm Improves Outcome After Aneurysmal Subarachnoid Hemorrhage: Rationale and Design of CONSCIOUS-2 and CONSCIOUS-3 Trials
R. Loch Macdonald et al.
NEUROCRITICAL CARE (2010)
Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial
R. Loch Macdonald et al.
STROKE (2008)
Influence of ethnic origin and sex on the pharmacokinetics of clazosentan
Paul L. M. van Giersbergen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution
R. Loch Macdonald et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist
Paul L. M. van Giersbergen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion
Paul L. M. van Giersbergen et al.
CLINICAL DRUG INVESTIGATION (2007)
Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study
P Vajkoczy et al.
JOURNAL OF NEUROSURGERY (2005)
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist
J Dingemanse et al.
CLINICAL PHARMACOKINETICS (2004)
Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage
J Sen et al.
LANCET NEUROLOGY (2003)
Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage
SA Mayer et al.
NEUROLOGY (2002)
Health outcomes 1 year after subarachnoid hemorrhage - An international population-based study
ML Hackett et al.
NEUROLOGY (2000)
Share Paper
